Amoxapine

CHEMBL1113 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

313.8 g/mol

LogP

2.6

Phase

4

A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.

分子量

313.8000 g/mol

LogP

2.60

TPSA

36.90 Å²

Lipinski 五规则

符合

作用机制

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2

InChI

InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

Molecular Formula

C17H16ClN3O

HBD / HBA

1 / 3

可旋转键数

1

重原子数

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Amoxapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1113. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2170. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Amoxapine 在 PillFYI 上

结构

快速数据

分子式: C17H16ClN3O

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.